Gynaecology: Endometrial — advanced/recurrent immunotherapy (RUBY)
Free question published 12 November 2026
A 67-year-old woman is referred with newly diagnosed primary advanced endometrial carcinoma, FIGO stage IVB with peritoneal and omental deposits found at diagnostic laparoscopy. Immunohistochemistry on the biopsy shows mismatch-repair deficiency (dMMR/MSI-high). Her ECOG performance status is 0 and renal function is normal, and the gynaecological oncology MDT is deciding whether to add a targeted or immune agent to standard chemotherapy. Which first-line systemic strategy offers the greatest progression-free survival benefit in this molecular subgroup?
- ACarboplatin and paclitaxel plus bevacizumab
- BSingle-agent hormonal therapy using a progestogen as the sole systemic treatment modality
- CCarboplatin and paclitaxel plus dostarlimab, followed by dostarlimab maintenance
- DSingle-agent olaparib
- ECarboplatin and paclitaxel alone
Why C is correct
In the RUBY trial, adding the anti-PD-1 antibody dostarlimab to carboplatin-paclitaxel (with dostarlimab maintenance) produced a large progression-free survival benefit in the dMMR/MSI-high population (hazard ratio about 0.30). This molecular subgroup is highly immunotherapy-sensitive, making chemo-immunotherapy the preferred first-line strategy.
And why the others are not
- AIncorrect. Bevacizumab is not the RUBY regimen; the trial added the immune checkpoint inhibitor dostarlimab.
- BIncorrect. Progestogen monotherapy is not the optimal first-line option for advanced dMMR endometrial cancer when chemo-immunotherapy is available.
- DIncorrect. Olaparib is a PARP inhibitor used in ovarian cancer maintenance, not first-line advanced endometrial cancer.
- EIncorrect. Chemotherapy alone is inferior to chemo-immunotherapy in the dMMR/MSI-high subgroup.
Source RUBY — dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer — Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer (ENGOT-EN6/GOG-3031/RUBY). N Engl J Med, 2023.
More free gynaecology questions
- Gynaecology: Cervix — adjuvant therapy after radical hysterectomy · 01 November 2026
- Gynaecology: Cervix — immunotherapy with chemoradiotherapy (KEYNOTE-A18) · 21 October 2026
- Gynaecology: Cervix — para-aortic nodal staging and management · 10 October 2026
Sitting in February? Follow the twenty-week plan.
2,500+ cited questions like this one are waiting in the vault.
See plans and pricing